![\"Facebook](\"\/themes\/custom\/nlr_theme\/images\/facebook_orange_212.png\")
<\/a> ![\"Twitter-X](\"\/themes\/custom\/nlr_theme\/images\/twitter_orange_212.png\")
<\/a> ![\"LinkedIn](\"\/themes\/custom\/nlr_theme\/images\/linkedin_orange_212.png\")
<\/a>
NYB.AI Vecura AI Scientist Powered By NVIDIA
NYB.AI launches Vecura 2.0, an agentic AI platform powered by NVIDIA technologies to accelerate molecular discovery and life science research.<\/i>
SINGAPORE, June 1, 2026 \/EINPresswire.com<\/a>\/ — Life science research is entering an AI era, but most discovery teams still cannot use frontier models at scale. Advanced AI models, molecular simulation tools, scientific databases, inference optimization and GPU infrastructure remain fragmented across separate systems. For many pharmaceutical companies, ingredient innovators, biotech teams, and research groups, this makes AI adoption slow, costly, and technically demanding.
NYB.AI<\/a>, a Singapore Artificial Intelligence (AI) technology startup developing infrastructure for molecular discovery and life science research, aims to address this gap with Vecura, its agentic AI platform that connects scientific models, biological data, molecular analysis tools, and GPU-accelerated computing into a unified discovery workflow.
Vecura 2.0 builds on the original Vecura 1.0 platform, which provided access to AI models and scientific tools for molecular discovery. With the new agentic layer, Vecura 2.0 moves beyond tool access toward workflow execution. It is designed to help research teams define scientific objectives, retrieve relevant context, activate suitable models, compare outputs, and generate structured decision support with less manual coordination.
From model access to agentic workflows
Vecura was built around a simple premise: the next barrier in AI for science is not access to more models. It is the ability to make those models work together in discovery settings. The original Vecura platform brought hundreds of AI models, scientific tools, biological data, and molecular analysis capabilities into connected workflows, helping research teams move across compound analysis, target exploration, formulation research, toxicity assessment, and translational R&D without relying on separate systems at every step.
Vecura 2.0 extends this foundation with an agentic AI layer. The upgraded platform is designed to reason across the workflow by understanding research objectives, retrieving relevant scientific context, selecting suitable models, coordinating execution, comparing outputs, and generating structured next-step recommendations. This evolves Vecura from a workflow platform into a more intelligent discovery system that can assist scientists at scale, closer to how real research decisions are made.
This agentic approach allows scientists to focus on research direction rather than infrastructure management. It also supports NYB.AI\u2019s broader vision to democratize molecular discovery by making advanced AI models, scientific tools, and GPU-intensive workflows more accessible to teams beyond large pharmaceutical organizations and specialized computational labs.
Scaling access through NVIDIA technologies
NYB.AI is strengthening Vecura\u2019s agentic architecture for scientific discovery using NVIDIA technologies. As a member of the NVIDIA Inception program for startups, NYB.AI received access to NVIDIA Hopper GPUs through the NVIDIA Innovation Lab<\/a>, along with engineering guidance to advance Vecura\u2019s ability to plan, execute, and coordinate complex research tasks. This support enables Vecura to move beyond isolated model execution toward connected workflows where scientific context, model selection, inference, comparison, and decision support operate as one system.
Vecura is powered by NVIDIA technologies spanning agentic orchestration, scientific modeling, data and retrieval, and production deployment – all running on NVIDIA accelerated computing<\/a>.
NYB.AI is also developing a token-based access model for Vecura 2.0. Through platform credits, biopharma companies, ingredient companies, and research teams can access AI-powered discovery workflows such as compound screening, bioactivity prediction, and molecular docking. This model allows users to run compute intensive scientific tasks through NYB.AI\u2019s platform without needing to build or operate their own infrastructure.
What\u2019s next?
NYB.AI is bringing Vecura 2.0 to the NVIDIA Inception Startup Showcase at the Inception Pavilion during InnoVEX 2026 (June 2\u20135, 2026, Taipei Nangang Exhibition Center). The showcase will give NYB.AI an opportunity to validate Vecura 2.0 with enterprise leaders, investors, ecosystem partners, and international buyers, and strengthens its visibility within NVIDIA Inception ecosystem \u2014 demonstrating how agentic AI can move beyond model experimentation into usable research infrastructure for molecular discovery teams.
At InnoVEX 2026, NYB.AI will demonstrate how Vecura 2.0 can support molecular discovery and life science research across pharmaceuticals, nutraceuticals, cosmetics, food science, functional ingredients, and consumer health. The platform reflects NYB.AI\u2019s broader mission to make advanced AI discovery infrastructure more usable, scalable, and accessible across the life science ecosystem.
About NYB.AI
NYB.AI is an AI biotechnology company developing infrastructure for molecular discovery and life science research, and a member of NVIDIA Inception. Its flagship platform, Vecura, is an agentic AI platform that connects AI models, scientific tools, biological data, retrieval systems, accelerated computing, and autonomous workflows to help life science teams shorten discovery cycles and prioritize high-potential candidates.
Quynh Nguyen
NYB.AI
quynh@nyb.ai
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above. ![\"\"](\"https:\/\/www.einpresswire.com\/tracking\/article.gif?aid=915998116§ion=einpresswire&a=I6oEA91avr5VEbsH&r=UGPdXcD4B62Mjydf&i=7RycnBz-_c1MN5tx\")
\u00a0
Sign Up for any (or all) of our 25+ Newsletters<\/font><\/a>
\u00a0
You are responsible for reading, understanding, and agreeing to the National Law Review’s (NLR\u2019s) and the National Law Forum LLC’s \u00a0Terms of Use<\/a> and Privacy Policy<\/a> before using the National Law Review website. The National Law Review is a free-to-use, no-log-in database<\/a> of legal and business articles.\u00a0The content and links on www.NatLawReview.com<\/a>\u00a0are intended for general information purposes only. Any legal analysis, legislative updates, or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys, or other professionals or organizations who include content on the National Law Review website.\u00a0If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor. \u00a0
Some states have laws and ethical rules regarding solicitation and advertisement practices by attorneys and\/or other professionals.\u00a0The National Law Review is not a law firm nor is www.NatLawReview.com<\/a> \u00a0intended to be a referral service for attorneys and\/or other professionals. The NLR does not wish, nor does it intend, to solicit the business of anyone or to refer anyone to an attorney or other professional. \u00a0NLR does not answer legal questions nor will we refer you to an attorney or other professional if you request such information from us.\u00a0
Under certain state laws, the following statements may be required on this website and we have included them in order to be in full compliance with these rules. The choice of a lawyer or other professional is an important decision and should not be based solely upon advertisements. Attorney Advertising Notice: Prior results do not guarantee a similar outcome. Statement in compliance with Texas Rules of Professional Conduct. Unless otherwise noted, attorneys are not certified by the Texas Board of Legal Specialization, nor can NLR attest to the accuracy of any notation of Legal Specialization or other Professional Credentials.
The National Law Review – National Law Forum LLC 2070 Green Bay Rd., Suite 178, Highland Park, IL 60035\u00a0 Telephone \u00a0(708) 357-3317 or\u00a0toll-free\u00a0(877)\u00a0357-3317.\u00a0 If you would like to contact us via email please click here.<\/a>
Copyright \u00a92026 National Law Forum, LLC<\/p>\n